Developmental Pharmacology of Hydroxyurea Across the Age Span for the Treatment of Sickle Cell Anemia
不同年龄段羟基脲治疗镰状细胞性贫血的发育药理学
基本信息
- 批准号:10382052
- 负责人:
- 金额:$ 19.6万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AdolescenceAdultAffectAgeAmericanApplications GrantsAttentionBeliefChildChildhoodClinicalClinical PharmacologyClinical TrialsCollaborationsDataData SetDevelopmentDiseaseDoseDrug KineticsErythrocytesFetal HemoglobinFundingFutureGene therapy trialGoalsGuidelinesHematological DiseaseHematologyHemoglobinHereditary DiseaseInheritedLifeLinkMaximum Tolerated DoseModelingMolecularMorbidity - disease rateMyelosuppressionNational Heart, Lung, and Blood InstituteNational Institute of Child Health and Human DevelopmentNucleic Acid Regulatory SequencesPatientsPediatric HematologyPharmaceutical PreparationsPharmacodynamicsPharmacogeneticsPharmacologyPhysiologicalPhysiologyPopulationPrecision therapeuticsRegimenResearchSafetySickle CellSickle Cell AnemiaSickle HemoglobinSolidSymptomsTimeToxic effectUnited States National Institutes of HealthWorkage relatedappropriate dosecohortdesigndose individualizationdrug metabolismeffective therapyexperiencegenome-widehydroxyureaimprovedindividual variationinfancyinhibitorinterpatient variabilitymethylomemortalitymultiple datasetsnovelnovel therapeuticspediatric patientspharmacometricspolymerizationprecision medicinepredict clinical outcomepreventprospectiveresearch studyresponsetranscriptometreatment response
项目摘要
PROJECT SUMMARY/ABSTRACT
Sickle cell anemia (SCA) is a devastating inherited blood disorder, affecting 100,000 Americans and millions
across the world. Without treatment, SCA results in tremendous morbidity and early mortality. Hydroxyurea is
the only pharmacologic therapy with proven benefits to ameliorate the clinical course of SCA. The clinical benefits
of hydroxyurea are due mostly to its ability to increase the expression of fetal hemoglobin (HbF), which prevents
sickling of red blood cells. The benefits of hydroxyurea are optimized when the expression of HbF is the highest,
which requires dose escalation to maximum tolerated dose (MTD) with a goal of mild myelosuppression.
However, due to the significant inter-individual heterogeneity in response to hydroxyurea treatment, and the
expertise and time required to escalate the dose effectively to MTD, most patients treated with hydroxyurea
receive suboptimal doses and have only modest treatment responses. Through the NIH-supported TREAT study
(NCT02286154), we have developed and prospectively evaluated an individualized, pharmacokinetics-guided
dosing model for children with SCA, designed to optimize the hydroxyurea dose and clinical response. This
dosing model has resulted in higher doses and robust HbF responses beyond what is seen with traditional dosing
and rivaling the goal of current curative gene therapy trials. These results suggest that early initiation of
hydroxyurea in the first year of life (while HbF is still expressed) using individualized dosing is a more effective
treatment model than traditional dosing strategies. Despite decades of hydroxyurea research and clinical
experience, no clear relationship of hydroxyurea exposure and clinical response has been established, and it
remains unclear how natural developmental physiology of drug metabolism or HbF expression and silencing
across the age span influence the effects of hydroxyurea. In this proposal, we aim to further characterize the
age-related developmental pharmacology of hydroxyurea in an effort to enhance the usage of this highly effective
therapy. Through these research efforts, we aim to quantitatively characterize the developmental
pharmacodynamics of hydroxyurea for children with SCA across the age span, to identify patient-specific
physiological predictors of clinical outcome, and to determine the optimal starting age and dosing regimen with
a goal of optimizing HbF response and clinical benefits. We also aim to further explore the robust HbF induction
for children starting hydroxyurea at a very early age to enhance our understanding of the mechanism by which
hydroxyurea induces HbF and whether this mechanism varies with age. This proposal is a research collaboration
between two strong co-PIs with expertise in pediatric hematology and clinical pharmacology and is an immediate
response to an important call from the NICHD to improve the safety and efficacy of pediatric precision therapies.
We will analyze multiple datasets from clinical trials across the world, including over 1000 children with SCA
treated with hydroxyurea. This research will provide a solid scientific basis for individualized dosing and will
improve our understanding of how and when to use hydroxyurea therapy for pediatric patients with SCA.
项目总结/摘要
镰状细胞性贫血(SCA)是一种毁灭性的遗传性血液疾病,影响10万美国人和数百万人。
在世界各地。如果不治疗,SCA会导致巨大的发病率和早期死亡率。羟基脲
是唯一一种经证实有益于改善SCA临床病程的药物治疗。的临床受益
主要是由于它能够增加胎儿血红蛋白(HbF)的表达,从而防止
红细胞的镰状化。当HbF的表达最高时,
其需要剂量递增至最大耐受剂量(MTD),目标是轻度骨髓抑制。
然而,由于对羟基脲治疗反应的显著个体间异质性,
有效递增剂量至MTD所需的专业知识和时间,大多数接受羟基脲治疗的患者
接受次优剂量并且只有适度的治疗反应。通过NIH支持的TREAT研究,
(NCT 02286154),我们开发并前瞻性评价了一种个体化的药代动力学指导的
SCA儿童的剂量模型,旨在优化羟基脲剂量和临床反应。这
给药模型导致了更高的剂量和稳健的HbF反应,超出了传统给药的效果
并与当前治愈性基因治疗试验的目标相媲美。这些结果表明,
在生命的第一年(当HbF仍然表达时)使用个体化给药是一种更有效的方法。
治疗模式比传统的给药策略。尽管几十年来对羟基脲的研究和临床
根据经验,尚未确定羟基脲暴露与临床反应的明确关系,
目前尚不清楚药物代谢或HbF表达和沉默的自然发育生理学
影响了羟基脲的作用。在本提案中,我们旨在进一步描述
年龄相关的发展药理学的羟基脲,努力提高使用这种高效
疗法通过这些研究工作,我们的目标是定量表征发展
在不同年龄段的SCA儿童中使用羟基脲的药效学,以确定患者特异性
临床结果的生理学预测因素,并确定最佳起始年龄和给药方案,
优化HbF反应和临床益处的目标。我们还旨在进一步探索HbF诱导的稳健性。
儿童在很小的时候就开始使用羟基脲,以加强我们对
羟基脲诱导HbF以及这种机制是否随年龄而变化。这是一个研究合作项目
两个具有儿科血液学和临床药理学专业知识的强有力的共同PI之间,
这是对NICHD提高儿科精确治疗安全性和有效性的重要呼吁的回应。
我们将分析来自世界各地临床试验的多个数据集,包括1000多名SCA儿童
用羟基脲处理。这项研究将为个体化给药提供坚实的科学基础,
提高我们对如何以及何时使用羟基脲治疗儿童SCA患者的理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Min Dong其他文献
Min Dong的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Min Dong', 18)}}的其他基金
Genome-wide CRISPR-Cas9 screens in insect cells to characterize insecticidal toxins
在昆虫细胞中进行全基因组 CRISPR-Cas9 筛选以表征杀虫毒素
- 批准号:
10873497 - 财政年份:2022
- 资助金额:
$ 19.6万 - 项目类别:
Genome-wide CRISPR-Cas9 screens in insect cells to characterize insecticidal toxins
在昆虫细胞中进行全基因组 CRISPR-Cas9 筛选以表征杀虫毒素
- 批准号:
10502624 - 财政年份:2022
- 资助金额:
$ 19.6万 - 项目类别:
Developmental Pharmacology of Hydroxyurea Across the Age Span for the Treatment of Sickle Cell Anemia
不同年龄段羟基脲治疗镰状细胞性贫血的发育药理学
- 批准号:
10551233 - 财政年份:2022
- 资助金额:
$ 19.6万 - 项目类别:
Model-Informed Evaluation of Hydroxyurea Exposure in Special Populations
特殊人群羟基脲暴露的模型知情评估
- 批准号:
10653016 - 财政年份:2022
- 资助金额:
$ 19.6万 - 项目类别:
Genome-wide CRISPR-Cas9 screens in insect cells to characterize insecticidal toxins
在昆虫细胞中进行全基因组 CRISPR-Cas9 筛选以表征杀虫毒素
- 批准号:
10646295 - 财政年份:2022
- 资助金额:
$ 19.6万 - 项目类别:
Model-Informed Evaluation of Hydroxyurea Exposure in Special Populations
特殊人群羟基脲暴露的模型知情评估
- 批准号:
10427738 - 财政年份:2022
- 资助金额:
$ 19.6万 - 项目类别:
Targeted delivery of therapeutics into motor neurons for post-exposure treatment of botulism
将治疗药物靶向输送至运动神经元,用于肉毒杆菌中毒的暴露后治疗
- 批准号:
10453725 - 财政年份:2021
- 资助金额:
$ 19.6万 - 项目类别:
Targeted delivery of therapeutics into motor neurons for post-exposure treatment of botulism
将治疗药物靶向输送至运动神经元,用于肉毒杆菌中毒的暴露后治疗
- 批准号:
10210524 - 财政年份:2021
- 资助金额:
$ 19.6万 - 项目类别:
Targeted Delivery of Therapeutics into Motor Neurons for Post-exposure Treatment of Botulism
将治疗药物靶向输送至运动神经元,用于肉毒杆菌中毒的暴露后治疗
- 批准号:
10653914 - 财政年份:2021
- 资助金额:
$ 19.6万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 19.6万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 19.6万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 19.6万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 19.6万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 19.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 19.6万 - 项目类别:
Discovery Early Career Researcher Award
RUI: Evaluation of Neurotrophic-Like properties of Spaetzle-Toll Signaling in the Developing and Adult Cricket CNS
RUI:评估发育中和成年蟋蟀中枢神经系统中 Spaetzle-Toll 信号传导的神经营养样特性
- 批准号:
2230829 - 财政年份:2023
- 资助金额:
$ 19.6万 - 项目类别:
Standard Grant
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 19.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 19.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 19.6万 - 项目类别:
Grant-in-Aid for Scientific Research (C)